BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Abstract

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL). Results of prospective clinical trials demonstrate the efficacy of venetoclax to salvage patients with disease progression on BTKis, but data on BTKi therapy after disease progression on venetoclax are limited, especially regarding durability of benefit. We retrospectively evaluated the records of 23 consecutive patients with relapsed/refractory CLL who received a BTKi (ibrutinib, n 5 21; zanubrutinib, n 5 2) after stopping venetoclax because of progressive disease. Median progression-free survival (PFS) and median overall survival after BT..